• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Safety

  • Print
  • Share
  • E-mail

Reyataz (atazanavir sulfate)

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) – October 2011

 

Summary View

 

ADVERSE REACTIONS

Clinical Trial Experience in Pediatric Patients
  • added safety data up to 96 weeks

 

also see:

 

CLINICAL PHARMACOLOGY

Pharmacokinetics, Pediatrics subsection

 

CLINICAL STUDIES

Pediatric Patients subsection